Format

Send to

Choose Destination
Euro Surveill. 2017 May 25;22(21). pii: 30540. doi: 10.2807/1560-7917.ES.2017.22.21.30540.

Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM).

Author information

1
Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
2
Department of Internal Medicine, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, Amsterdam, the Netherlands.
3
Department of Medical Microbiology, Academic Medical Center, Amsterdam, the Netherlands.
4
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
5
St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
6
STI Outpatient Clinic, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
7
The members of the group are listed at the end of the article.

Abstract

Current guidelines recommend hepatitis C virus (HCV) testing for HIV-infected men who have sex with men (MSM) with ongoing risk behaviour, without specifying the type of risk behaviour. We developed and validated the HCV-MOSAIC risk score to assist HCV testing in HIV-infected MSM. The risk score consisted of six self-reported risk factors identified using multivariable logistic regression using data from the Dutch MOSAIC study (n = 213, 2009-2013). Area under the ROC curve (AUC), sensitivity, specificity, post-test-probability-of-disease and diagnostic gain were calculated. The risk score was validated in case-control studies from Belgium (n = 142, 2010-2013) and the United Kingdom (n = 190, 2003-2005) and in cross-sectional surveys at a Dutch sexually transmitted infections clinic (n = 284, 2007-2009). The AUC was 0.82; sensitivity 78.0% and specificity 78.6%. In the validation studies sensitivity ranged from 73.1% to 100% and specificity from 56.2% to 65.6%. The post-test-probability-of-disease ranged from 5.9% to 20.0% given acute HCV prevalence of 1.7% to 6.4%, yielding a diagnostic gain of 4.2% to 13.6%. The HCV-MOSAIC risk score can successfully identify HIV-infected MSM at risk for acute HCV infection. It could be a promising tool to improve HCV testing strategies in various settings.

KEYWORDS:

MSM; clinical prediction rule; diagnosis; hepatitis C; risk score; testing

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for European Centre for Disease Prevention and Control (ECDC) Icon for PubMed Central
Loading ...
Support Center